News | October 01, 2013

FDA Approves Medtronic’s SE Stent for Use in Superficial Femoral, Proximal Popliteal Arteries

New indications for self-expanding device address broad area of peripheral artery disease

stent peripheral artery disease treatment complete se medtronic

October 1, 2013 — The U.S. Food and Drug Administration (FDA) approved Medtronic Inc.'s Complete SE (self-expanding) vascular stent for use in the lower extremities, specifically the superficial femoral artery (SFA) and proximal popliteal artery (PPA), which carry blood through the upper legs.

The FDA originally approved the same device for use in the iliac arteries, which perfuse the pelvis. It also has the Conformité Européene (CE) mark for iliac and, most recently, SFA and PPA indications.

The Complete SE SFA study, an independently adjudicated single-arm multicenter trial that enrolled 196 patients at 28 sites in the United States and Europe, supported FDA approval of the new SFA and PPA indications. The study showed a clinically driven target lesion revascularization (repeat procedure) rate of 8.4 percent at 12 months, which is among the best performances in clinical trials of contemporary self-expanding peripheral stents for the treatment of SFA/PPA lesions.

Additionally, there were no in-hospital major adverse events (MAE) among study patients, and the total MAE rate at 12 months was 11 percent. The Kaplan-Meier estimate of primary patency at 360 days was 90.9 percent; at the time of the last duplex ultrasound assessment (553 days), primary patency was 72.5 percent. No stent fractures occurred through 12 months.

The study also showed statistically significant improvements in multiple measures of clinical and functional effectiveness:

  • More than 80% of the patients had achieved a Rutherford classification of 0 or 1, the favorable end of the 0–6 scale, at 30 days, and that benefit persisted through six months and one year of follow-up.
  • On walking assessment measures at 12 months, absolute improvement in impairment was 37%, distance was 32%, speed was 22% and stair climbing was 23%.
  • 65% of the patients showed an improvement of 0.15 or more on their ankle-brachial index (ABI) or toe-brachial index (TBI) scores over the 12-month follow-up period. The mean ABI/TBI score at 12 months was 0.9.

These outcomes were achieved despite the challenging nature of the patient population:

  • 45% of the patients had diabetes, and 67% had a Rutherford classification of 3 or higher at baseline.
  • 50% of the treated lesions were located in the distal segment of the artery, and 91% were moderately or highly calcified.

“The Complete SE vascular stent has demonstrated compelling clinical results in this study, which included a broad spectrum of patient and lesion types,” said John Laird, M.D., primary investigator and medical director of the UC Davis Vascular Center near Sacramento. “It is also among the most deliverable and easy-to-use devices of its kind.”

For more information:

Related Content

Critical Limb Ischemia Treatment Shows No Improvement at Three Months
News | Peripheral Artery Disease (PAD) | March 23, 2018
Patients with foot ulcers or gangrene who received the experimental drug JVS-100 did not show evidence of faster wound...
FDA Clears Corindus CorPath GRX for Peripheral Vascular Interventions
Technology | Peripheral Artery Disease (PAD) | February 20, 2018
Corindus Vascular Robotics Inc. announced today that it received 510(k) clearance from the U.S. Food and Drug...
News | Peripheral Artery Disease (PAD) | December 29, 2017
December 29, 2017 — iVascular announced the release of the new Oceanus 14 Pro percutaneous transluminal angioplasty (
Lesion Preparation Via Atherectomy Enhances Paclitaxel Distribution in Calcified Peripheral Arteries
News | Peripheral Artery Disease (PAD) | September 20, 2017
September 20, 2017 — Not-for-profit preclinical research institute CBSET announced that its scientists have published
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD) | September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Philips Showcases Integrated Vascular Solutions at VIVA 2017
News | Peripheral Artery Disease (PAD) | September 13, 2017
Philips announced its presence at the Vascular Interventional Advances (VIVA 17) Annual Conference in Las Vegas from...
PQ Bypass Reports Positive Results for Detour System in Patients With Long Femoropopliteal Blockages
News | Peripheral Artery Disease (PAD) | September 13, 2017
A subset analysis of the DETOUR I clinical trial showed promising safety and effectiveness results of PQ Bypass’ Detour...
Ra Medical Systems Granted Broad Patent for DABRA Catheter
News | Peripheral Artery Disease (PAD) | August 09, 2017
August 9, 2017 — Ra Medical Systems announced that the United States Patent and Trademark Office (USPTO) has granted
The LimFlow Percutaneous Deep Vein Arterialization System (pDVA) converts veins into arteries to restore blood flow in critical limb ischemia (CLI).

The LimFlow Percutaneous Deep Vein Arterialization System (pDVA) converts veins into arteries to restore blood flow in critical limb ischemia (CLI). This image shows how the covered stents used with the system connect to create a new arterial pathway.

News | Peripheral Artery Disease (PAD) | August 02, 2017
Sponsored Content | Videos | Peripheral Artery Disease (PAD) | July 25, 2017
This video case study, provided by Gore Medical, is titled "Tackling Complex Cases in Dialysis Access," by John Ross,
Overlay Init